XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Other Events
Item 8.01
On March 13, 2019, Xenon Pharmaceuticals Inc. (the Company) announced the meeting, record date and certain other information relating to its 2019 annual meeting of shareholders to a filing submitted to the System for Electronic Document Analysis and Retrieval (SEDAR) in Canada.
A copy of the filing submitted to SEDAR is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits.
Xenon Pharmaceuticals Inc. Exhibit
EX-99.1 2 xene-ex991_6.htm EX-99.1 xene-ex991_6.htm Exhibit 99.1 Craig Colosso Relationship Manager American Stock Transfer & Trust Company,…
To view the full exhibit click here
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.
